Depomed (DEPO) Tops Q4 EPS by 5c

Depomed (NASDAQ: DEPO) reported Q4 EPS of $0.15, $0.05 better than the analyst estimate of $0.10. Revenue for the quarter came in at $94 million versus the consensus estimate of $90.94 million.

For earnings history and earnings-related data on Depomed (DEPO) click here.

You May Also Be Interested In

• VNET Group (VNET) Misses Q2 EPS by 164c
• iQIYI (IQ) Misses Q2 EPS by 21c
• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance